For HPV types phylogenetically related to HPV-18 (A7 species – including HPV types 39,45,59,68), evidence was mixed, with suggestion for

efficacy against HPV-68 (which in our testing system was indistinguishable from non-oncogenic HPV-73) but not for other types related to HPV-18. Finally, when CIN2+ cases were examined irrespective of HPV type, we observed over 60% efficacy, an effect that increased to >75% when our exploratory criteria were used to define incident outcomes. It is important to note that such estimates of overall efficacy are likely to be population specific and to vary depending on the proportion of infections in NLG919 price the population attributable to vaccine types, non-vaccine HPV types for which there is cross-protection, and non-vaccine HPV types for which there is no cross-protection. In fact, vaccine efficacy against

non-vaccine types or irrespective of HPV type reported from phase III randomized clinical trials to date have varied considerably as summarized in Table 4. It is not fully understood to what extent these observed differences are due to differences in study design and analysis (e.g. differences in colposcopy algorithm, sensitivity/specificity of HPV assays, and analytical cohorts evaluated), chance (95% confidence intervals tend to overlap), Y-27632 concentration population differences (e.g. differences in relative distribution of non-vaccine HPV types in different study populations), or vaccine differences (i.e. real differences in cross protection between the bivalent and quadrivalent vaccines). In a recent evaluation of this issue, we have noted that differences observed in efficacy estimates between FUTURE I/II and PATRICIA are likely explained by a combination Rolziracetam of these various factors [23]. We saw no evidence of waning efficacy during the study period. When we evaluated efficacy against HPV-16/18 infection over time, high efficacy (>80%) was observed in years 2–4+ and the lowest efficacy estimate

was observed in the first year of follow-up (57%). The high efficacy observed in the out years is consistent with evidence of long-term protection up to 8.4 years (HPV-16/18 vaccine) and 5 years (HPV-6/11/16/18 vaccine) in the pharmaceutical trials [29] and [30]. We interpret the somewhat reduced efficacy in year 1 as suggestive that some outcomes might have resulted from undetected infections present before vaccination in our group of largely sexually experienced women [12]. The safety and immunogenicity profile of VLP-based vaccine have been evaluated in large-scale trials and results suggest that that vaccine has an acceptable safety profile, is generally well tolerated, and induces a robust and sustained immune responses [7], [30], [31], [32], [33], [34] and [35]. Safety results from our trial are consistent with these previous reports.